<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2024//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_240101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">36301489</PMID><DateCompleted><Year>2023</Year><Month>02</Month><Day>23</Day></DateCompleted><DateRevised><Year>2023</Year><Month>02</Month><Day>23</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1699-3055</ISSN><JournalIssue CitedMedium="Internet"><Volume>25</Volume><Issue>3</Issue><PubDate><Year>2023</Year><Month>Mar</Month></PubDate></JournalIssue><Title>Clinical &amp; translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico</Title><ISOAbbreviation>Clin Transl Oncol</ISOAbbreviation></Journal><ArticleTitle>CD155 is a putative therapeutic target in medulloblastoma.</ArticleTitle><Pagination><StartPage>696</StartPage><EndPage>705</EndPage><MedlinePgn>696-705</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1007/s12094-022-02975-9</ELocationID><Abstract><AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">Medulloblastoma is the most common pediatric malignant brain tumor, consisting of four molecular subgroups (WNT, SHH, Group 3, Group 4) and 12 subtypes. Expression of the cell surface poliovirus receptor (PVR), CD155, is necessary for entry of the viral immunotherapeutic agent, PVSRIPO, a polio:rhinovirus chimera. CD155, physiologically expressed in the mononuclear phagocytic system, is widely expressed ectopically in solid tumors. The objective of this study is to elucidate CD155 expression as both a receptor for PVSRIPO and a therapeutic target in medulloblastoma.</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">PVR mRNA expression was determined in several patient cohorts and human medulloblastoma cell lines. Patient samples were also analyzed for CD155 expression using immunohistochemistry and cell lines were analyzed using Western Blots. CD155 was blocked using a monoclonal antibody and cell viability, invasion, and migration were assessed.</AbstractText><AbstractText Label="RESULTS AND DISCUSSION" NlmCategory="CONCLUSIONS">PVR mRNA expression was highest in the WNT subgroup and lowest in Group 4. PVR expression in the subgroups of medulloblastoma were similar to other pediatric brain and non-brain tumors. PVR expression was largely not associated with subgroup or subtype. Neither PVR protein expression intensity nor frequency were associated with overall survival. PVR expression was elevated in Group 3 patients with metastases but there was no difference in paired primary and metastatic medulloblastoma. Blocking PVR resulted in dose-dependent cell death, decreased invasion in vitro, and modestly inhibited cell migration.</AbstractText><AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">CD155 is expressed across medulloblastoma subgroups and subtypes. Blocking CD155 results in cell death and decreased cellular invasion. This study provides rationale for CD155-targeting agents including PVSRIPO and antibody-mediated blockade of CD155.</AbstractText><CopyrightInformation>&#xa9; 2022. The Author(s), under exclusive licence to Federaci&#xf3;n de Sociedades Espa&#xf1;olas de Oncolog&#xed;a (FESEO).</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Li</LastName><ForeName>Sean</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Duke University, Durham, NC, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>McLendon</LastName><ForeName>Roger</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>Department of Pathology, Duke University, Durham, NC, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Sankey</LastName><ForeName>Eric</ForeName><Initials>E</Initials><AffiliationInfo><Affiliation>Department of Neurosurgery, Duke University Medical Center, Box 3272, Durham, NC, 27710, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kornahrens</LastName><ForeName>Reb</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>Department of Neurosurgery, Duke University Medical Center, Box 3272, Durham, NC, 27710, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lyne</LastName><ForeName>Anne-Marie</ForeName><Initials>AM</Initials><AffiliationInfo><Affiliation>Institut Curie, PSL Research University, 75005, Paris, France.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Inserm, U900, Paris, France.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>MINES ParisTech, CBIO, Centre for Computational Biology, PSL Research University, 75006, Paris, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Cavalli</LastName><ForeName>Florence Marie G&#xe9;raldine</ForeName><Initials>FMG</Initials><AffiliationInfo><Affiliation>Institut Curie, PSL Research University, 75005, Paris, France.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Inserm, U900, Paris, France.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>MINES ParisTech, CBIO, Centre for Computational Biology, PSL Research University, 75006, Paris, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>McKay</LastName><ForeName>Zachary</ForeName><Initials>Z</Initials><AffiliationInfo><Affiliation>Department of Neurosurgery, Duke University Medical Center, Box 3272, Durham, NC, 27710, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Herndon</LastName><ForeName>James Emmett</ForeName><Initials>JE</Initials><Suffix>2nd</Suffix><AffiliationInfo><Affiliation>Department of Biostatistics and Bioinformatics, Duke University School of Medicine, Durham, NC, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Remke</LastName><ForeName>Marc</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Department of Pediatric Oncology, Hematology, and Clinical Immunology, Medical Faculty, University Hospital D&#xfc;sseldorf, D&#xfc;sseldorf, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Picard</LastName><ForeName>Daniel</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>Department of Pediatric Oncology, Hematology, and Clinical Immunology, Medical Faculty, University Hospital D&#xfc;sseldorf, D&#xfc;sseldorf, Germany.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Pediatric Neuro-Oncogenomics, German Cancer Consortium (DKTK) and German Cancer Research Center (DKFZ), Heidelberg, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Gromeier</LastName><ForeName>Matthias</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Department of Neurosurgery, Duke University Medical Center, Box 3272, Durham, NC, 27710, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Brown</LastName><ForeName>Michael</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Department of Neurosurgery, Duke University Medical Center, Box 3272, Durham, NC, 27710, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Thompson</LastName><ForeName>Eric Michael</ForeName><Initials>EM</Initials><Identifier Source="ORCID">0000-0003-2796-9914</Identifier><AffiliationInfo><Affiliation>Department of Pathology, Duke University, Durham, NC, USA. eric.thompson@duke.edu.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Neurosurgery, Duke University Medical Center, Box 3272, Durham, NC, 27710, USA. eric.thompson@duke.edu.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>CA171067</GrantID><Agency>U.S. Department of Defense</Agency><Country/></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2022</Year><Month>10</Month><Day>27</Day></ArticleDate></Article><MedlineJournalInfo><Country>Italy</Country><MedlineTA>Clin Transl Oncol</MedlineTA><NlmUniqueID>101247119</NlmUniqueID><ISSNLinking>1699-048X</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C066100">poliovirus receptor</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D012333">RNA, Messenger</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D002648" MajorTopicYN="N">Child</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008527" MajorTopicYN="Y">Medulloblastoma</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001932" MajorTopicYN="Y">Brain Neoplasms</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D017955" MajorTopicYN="Y">Poliovirus</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D002528" MajorTopicYN="Y">Cerebellar Neoplasms</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012333" MajorTopicYN="N">RNA, Messenger</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">CD155</Keyword><Keyword MajorTopicYN="N">Medulloblastoma</Keyword><Keyword MajorTopicYN="N">PVR</Keyword><Keyword MajorTopicYN="N">Poliovirus receptor</Keyword><Keyword MajorTopicYN="N">Target</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2022</Year><Month>7</Month><Day>28</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2022</Year><Month>10</Month><Day>5</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2022</Year><Month>10</Month><Day>28</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2023</Year><Month>2</Month><Day>25</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2022</Year><Month>10</Month><Day>27</Day><Hour>11</Hour><Minute>30</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">36301489</ArticleId><ArticleId IdType="doi">10.1007/s12094-022-02975-9</ArticleId><ArticleId IdType="pii">10.1007/s12094-022-02975-9</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>CDC. National Center for Health Statistics. During the 1999&#x2013;2014 period, brain cancer replaced leukemia as the most common cancer causing death in children and adolescents aged 1&#x2013;19 years 2016.</Citation></Reference><Reference><Citation>Martin AM, Raabe E, Eberhart C, Cohen KJ. Management of pediatric and adult patients with medulloblastoma. Curr Treat Options Oncol. 2014;15(4):581&#x2013;94.</Citation><ArticleIdList><ArticleId IdType="pubmed">25194927</ArticleId><ArticleId IdType="pmc">4216607</ArticleId><ArticleId IdType="doi">10.1007/s11864-014-0306-4</ArticleId></ArticleIdList></Reference><Reference><Citation>Thompson EM, Hielscher T, Bouffet E, Remke M, Luu B, Gururangan S, et al. Prognostic value of medulloblastoma extent of resection after accounting for molecular subgroup: a retrospective integrated clinical and molecular analysis. Lancet Oncol. 2016;17(4):484&#x2013;95.</Citation><ArticleIdList><ArticleId IdType="pubmed">26976201</ArticleId><ArticleId IdType="pmc">4907853</ArticleId><ArticleId IdType="doi">10.1016/S1470-2045(15)00581-1</ArticleId></ArticleIdList></Reference><Reference><Citation>Mulhern RK, Palmer SL, Merchant TE, Wallace D, Kocak M, Brouwers P, et al. Neurocognitive consequences of risk-adapted therapy for childhood medulloblastoma. J Clin Oncol. 2005;23(24):5511&#x2013;9.</Citation><ArticleIdList><ArticleId IdType="pubmed">16110011</ArticleId><ArticleId IdType="doi">10.1200/JCO.2005.00.703</ArticleId></ArticleIdList></Reference><Reference><Citation>Yock TI, Yeap BY, Ebb DH, Weyman E, Eaton BR, Sherry NA, et al. Long-term toxic effects of proton radiotherapy for paediatric medulloblastoma: a phase 2 single-arm study. Lancet Oncol. 2016;17(3):287&#x2013;98.</Citation><ArticleIdList><ArticleId IdType="pubmed">26830377</ArticleId><ArticleId IdType="doi">10.1016/S1470-2045(15)00167-9</ArticleId></ArticleIdList></Reference><Reference><Citation>Paulino AC, Lobo M, Teh BS, Okcu MF, South M, Butler EB, et al. Ototoxicity after intensity-modulated radiation therapy and cisplatin-based chemotherapy in children with medulloblastoma. Int J Radiat Oncol Biol Phys. 2010;78(5):1445&#x2013;50.</Citation><ArticleIdList><ArticleId IdType="pubmed">20231075</ArticleId><ArticleId IdType="doi">10.1016/j.ijrobp.2009.09.031</ArticleId></ArticleIdList></Reference><Reference><Citation>Thompson EM, Brown M, Dobrikova E, Ramaswamy V, Taylor MD, McLendon R, et al. Poliovirus receptor (CD155) expression in pediatric brain tumors mediates oncolysis of medulloblastoma and pleomorphic xanthoastrocytoma. J Neuropathol Exp Neurol. 2018;77(8):696&#x2013;702.</Citation><ArticleIdList><ArticleId IdType="pubmed">29878245</ArticleId><ArticleId IdType="pmc">6044395</ArticleId><ArticleId IdType="doi">10.1093/jnen/nly045</ArticleId></ArticleIdList></Reference><Reference><Citation>Taylor MD, Northcott PA, Korshunov A, Remke M, Cho YJ, Clifford SC, et al. Molecular subgroups of medulloblastoma: the current consensus. Acta Neuropathol. 2012;123(4):465&#x2013;72.</Citation><ArticleIdList><ArticleId IdType="pubmed">22134537</ArticleId><ArticleId IdType="doi">10.1007/s00401-011-0922-z</ArticleId></ArticleIdList></Reference><Reference><Citation>Thompson EM, Ashley D, Landi D. Current medulloblastoma subgroup specific clinical trials. Transl Pediatr. 2020;9(2):157&#x2013;62.</Citation><ArticleIdList><ArticleId IdType="pubmed">32477916</ArticleId><ArticleId IdType="pmc">7237968</ArticleId><ArticleId IdType="doi">10.21037/tp.2020.03.03</ArticleId></ArticleIdList></Reference><Reference><Citation>Cavalli FMG, Remke M, Rampasek L, Peacock J, Shih DJH, Luu B, et al. Intertumoral heterogeneity within medulloblastoma subgroups. Cancer Cell. 2017;31(6):737&#x2013;54.</Citation><ArticleIdList><ArticleId IdType="pubmed">28609654</ArticleId><ArticleId IdType="pmc">6163053</ArticleId><ArticleId IdType="doi">10.1016/j.ccell.2017.05.005</ArticleId></ArticleIdList></Reference><Reference><Citation>Mendelsohn CL, Wimmer E, Racaniello VR. Cellular receptor for poliovirus: molecular cloning, nucleotide sequence, and expression of a new member of the immunoglobulin superfamily. Cell. 1989;56(5):855&#x2013;65.</Citation><ArticleIdList><ArticleId IdType="pubmed">2538245</ArticleId><ArticleId IdType="doi">10.1016/0092-8674(89)90690-9</ArticleId></ArticleIdList></Reference><Reference><Citation>Brown MC, Mosaheb MM, Mohme M, McKay ZP, Holl EK, Kastan JP, et al. Viral infection of cells within the tumor microenvironment mediates antitumor immunotherapy via selective TBK1-IRF3 signaling. Nat Commun. 2021;12(1):1858.</Citation><ArticleIdList><ArticleId IdType="pubmed">33767151</ArticleId><ArticleId IdType="pmc">7994570</ArticleId><ArticleId IdType="doi">10.1038/s41467-021-22088-1</ArticleId></ArticleIdList></Reference><Reference><Citation>Brown MC, Dobrikova EY, Dobrikov MI, Walton RW, Gemberling SL, Nair SK, et al. Oncolytic polio virotherapy of cancer. Cancer. 2014;120(21):3277&#x2013;86.</Citation><ArticleIdList><ArticleId IdType="pubmed">24939611</ArticleId><ArticleId IdType="doi">10.1002/cncr.28862</ArticleId></ArticleIdList></Reference><Reference><Citation>Ogita H, Ikeda W, Takai Y. Roles of cell adhesion molecules nectin and nectin-like molecule-5 in the regulation of cell movement and proliferation. J Microsc. 2008;231(3):455&#x2013;65.</Citation><ArticleIdList><ArticleId IdType="pubmed">18755001</ArticleId><ArticleId IdType="doi">10.1111/j.1365-2818.2008.02058.x</ArticleId></ArticleIdList></Reference><Reference><Citation>Sloan KE, Stewart JK, Treloar AF, Matthews RT, Jay DG. CD155/PVR enhances glioma cell dispersal by regulating adhesion signaling and focal adhesion dynamics. Can Res. 2005;65(23):10930&#x2013;7.</Citation><ArticleIdList><ArticleId IdType="doi">10.1158/0008-5472.CAN-05-1890</ArticleId></ArticleIdList></Reference><Reference><Citation>Thompson EM, Whitney NL, Wu YJ, Neuwelt EA. The effect of alpha-v integrin inhibition on the malignant characteristics of medulloblastoma. J Neurosurg Pediatr. 2013;11(1):60&#x2013;7.</Citation><ArticleIdList><ArticleId IdType="pubmed">23082872</ArticleId><ArticleId IdType="doi">10.3171/2012.9.PEDS12268</ArticleId></ArticleIdList></Reference><Reference><Citation>Chiang EY, Mellman I. TIGIT-CD226-PVR axis: advancing immune checkpoint blockade for cancer immunotherapy. J Immunother Cancer. 2022;10(4):e004711.</Citation><ArticleIdList><ArticleId IdType="pubmed">35379739</ArticleId><ArticleId IdType="pmc">8981293</ArticleId><ArticleId IdType="doi">10.1136/jitc-2022-004711</ArticleId></ArticleIdList></Reference><Reference><Citation>Berchtold NC, Cribbs DH, Coleman PD, Rogers J, Head E, Kim R, et al. Gene expression changes in the course of normal brain aging are sexually dimorphic. Proc Natl Acad Sci USA. 2008;105(40):15605&#x2013;10.</Citation><ArticleIdList><ArticleId IdType="pubmed">18832152</ArticleId><ArticleId IdType="pmc">2563070</ArticleId><ArticleId IdType="doi">10.1073/pnas.0806883105</ArticleId></ArticleIdList></Reference><Reference><Citation>Robinson G, Parker M, Kranenburg TA, Lu C, Chen X, Ding L, et al. Novel mutations target distinct subgroups of medulloblastoma. Nature. 2012;488(7409):43&#x2013;8.</Citation><ArticleIdList><ArticleId IdType="pubmed">22722829</ArticleId><ArticleId IdType="pmc">3412905</ArticleId><ArticleId IdType="doi">10.1038/nature11213</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang X, Dubuc AM, Ramaswamy V, Mack S, Gendoo DM, Remke M, et al. Medulloblastoma subgroups remain stable across primary and metastatic compartments. Acta Neuropathol. 2015;129(3):449&#x2013;57.</Citation><ArticleIdList><ArticleId IdType="pubmed">25689980</ArticleId><ArticleId IdType="pmc">4333718</ArticleId><ArticleId IdType="doi">10.1007/s00401-015-1389-0</ArticleId></ArticleIdList></Reference><Reference><Citation>Grobner SN, Worst BC, Weischenfeldt J, Buchhalter I, Kleinheinz K, Rudneva VA, et al. The landscape of genomic alterations across childhood cancers. Nature. 2018;555(7696):321&#x2013;7.</Citation><ArticleIdList><ArticleId IdType="pubmed">29489754</ArticleId><ArticleId IdType="doi">10.1038/nature25480</ArticleId></ArticleIdList></Reference><Reference><Citation>Thompson EM, Keir ST, Venkatraman T, Lascola C, Yeom KW, Nixon AB, et al. The role of angiogenesis in Group 3 medulloblastoma pathogenesis and survival. Neuro Oncol. 2017;19(9):1217&#x2013;27.</Citation><ArticleIdList><ArticleId IdType="pubmed">28379574</ArticleId><ArticleId IdType="pmc">5570262</ArticleId><ArticleId IdType="doi">10.1093/neuonc/nox033</ArticleId></ArticleIdList></Reference><Reference><Citation>Northcott PA, Lee C, Zichner T, Stutz AM, Erkek S, Kawauchi D, et al. Enhancer hijacking activates GFI1 family oncogenes in medulloblastoma. Nature. 2014;511(7510):428&#x2013;34.</Citation><ArticleIdList><ArticleId IdType="pubmed">25043047</ArticleId><ArticleId IdType="pmc">4201514</ArticleId><ArticleId IdType="doi">10.1038/nature13379</ArticleId></ArticleIdList></Reference><Reference><Citation>McLendon RE, Lipp E, Satterfield D, Ehinger M, Austin A, Fleming D, et al. Prognostic marker analysis in pediatric intracranial ependymomas. J Neurooncol. 2015;122(2):255&#x2013;61.</Citation><ArticleIdList><ArticleId IdType="pubmed">25563815</ArticleId><ArticleId IdType="doi">10.1007/s11060-014-1711-z</ArticleId></ArticleIdList></Reference><Reference><Citation>Ellison DW, Dalton J, Kocak M, Nicholson SL, Fraga C, Neale G, et al. Medulloblastoma: clinicopathological correlates of SHH, WNT, and non-SHH/WNT molecular subgroups. Acta Neuropathol. 2011;121(3):381&#x2013;96.</Citation><ArticleIdList><ArticleId IdType="pubmed">21267586</ArticleId><ArticleId IdType="pmc">3519926</ArticleId><ArticleId IdType="doi">10.1007/s00401-011-0800-8</ArticleId></ArticleIdList></Reference><Reference><Citation>Northcott PA, Korshunov A, Witt H, Hielscher T, Eberhart CG, Mack S, et al. Medulloblastoma comprises four distinct molecular variants. J Clin Oncol. 2011;29(11):1408&#x2013;14.</Citation><ArticleIdList><ArticleId IdType="pubmed">20823417</ArticleId><ArticleId IdType="doi">10.1200/JCO.2009.27.4324</ArticleId></ArticleIdList></Reference><Reference><Citation>Friedman HS, Burger PC, Bigner SH, Trojanowski JQ, Wikstrand CJ, Halperin EC, et al. Establishment and characterization of the human medulloblastoma cell line and transplantable xenograft D283 Med. J Neuropathol Exp Neurol. 1985;44(6):592&#x2013;605.</Citation><ArticleIdList><ArticleId IdType="pubmed">4056828</ArticleId><ArticleId IdType="doi">10.1097/00005072-198511000-00005</ArticleId></ArticleIdList></Reference><Reference><Citation>Friedman HS, Burger PC, Bigner SH, Trojanowski JQ, Brodeur GM, He XM, et al. Phenotypic and genotypic analysis of a human medulloblastoma cell line and transplantable xenograft (D341 Med) demonstrating amplification of c-myc. Am J Pathol. 1988;130(3):472&#x2013;84.</Citation><ArticleIdList><ArticleId IdType="pubmed">3279793</ArticleId><ArticleId IdType="pmc">1880676</ArticleId></ArticleIdList></Reference><Reference><Citation>He XM, Wikstrand CJ, Friedman HS, Bigner SH, Pleasure S, Trojanowski JQ, et al. Differentiation characteristics of newly established medulloblastoma cell lines (D384 Med, D425 Med, and D458 Med) and their transplantable xenografts. Lab Invest. 1991;64(6):833&#x2013;43.</Citation><ArticleIdList><ArticleId IdType="pubmed">1904513</ArticleId></ArticleIdList></Reference><Reference><Citation>Hare CB, Elion GB, Houghton PJ, Houghton JA, Keir S, Marcelli SL, et al. Therapeutic efficacy of the topoisomerase I inhibitor 7-ethyl-10-(4-[1-piperidino]-1-piperidino)-carbonyloxy-camptothecin against pediatric and adult central nervous system tumor xenografts. Cancer Chemother Pharmacol. 1997;39(3):187&#x2013;91.</Citation><ArticleIdList><ArticleId IdType="pubmed">8996518</ArticleId><ArticleId IdType="doi">10.1007/s002800050558</ArticleId></ArticleIdList></Reference><Reference><Citation>Aldosari N, Wiltshire RN, Dutra A, Schrock E, McLendon RE, Friedman HS, et al. Comprehensive molecular cytogenetic investigation of chromosomal abnormalities in human medulloblastoma cell lines and xenograft. Neuro Oncol. 2002;4(2):75&#x2013;85.</Citation><ArticleIdList><ArticleId IdType="pubmed">11916498</ArticleId><ArticleId IdType="pmc">1920654</ArticleId><ArticleId IdType="doi">10.1093/neuonc/4.2.75</ArticleId></ArticleIdList></Reference><Reference><Citation>Lindsey JC, Lusher ME, Anderton JA, Bailey S, Gilbertson RJ, Pearson AD, et al. Identification of tumour-specific epigenetic events in medulloblastoma development by hypermethylation profiling. Carcinogenesis. 2004;25(5):661&#x2013;8.</Citation><ArticleIdList><ArticleId IdType="pubmed">14688019</ArticleId><ArticleId IdType="doi">10.1093/carcin/bgh055</ArticleId></ArticleIdList></Reference><Reference><Citation>Ivanov DP, Coyle B, Walker DA, Grabowska AM. In vitro models of medulloblastoma: choosing the right tool for the job. J Biotechnol. 2016;20(236):10&#x2013;25.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jbiotec.2016.07.028</ArticleId></ArticleIdList></Reference><Reference><Citation>Thompson EM, Pishko GL, Muldoon LL, Neuwelt EA. Inhibition of SUR1 decreases the vascular permeability of cerebral metastases. Neoplasia. 2013;15(5):535&#x2013;43.</Citation><ArticleIdList><ArticleId IdType="pubmed">23633925</ArticleId><ArticleId IdType="pmc">3638356</ArticleId><ArticleId IdType="doi">10.1593/neo.13164</ArticleId></ArticleIdList></Reference><Reference><Citation>Suarez-Arnedo A, Torres Figueroa F, Clavijo C, Arbelaez P, Cruz JC, Munoz-Camargo C. An image J plugin for the high throughput image analysis of in vitro scratch wound healing assays. PLoS ONE. 2020;15(7): e0232565.</Citation><ArticleIdList><ArticleId IdType="pubmed">32722676</ArticleId><ArticleId IdType="pmc">7386569</ArticleId><ArticleId IdType="doi">10.1371/journal.pone.0232565</ArticleId></ArticleIdList></Reference><Reference><Citation>Lange R, Peng X, Wimmer E, Lipp M, Bernhardt G. The poliovirus receptor CD155 mediates cell-to-matrix contacts by specifically binding to vitronectin. Virology. 2001;285(2):218&#x2013;27.</Citation><ArticleIdList><ArticleId IdType="pubmed">11437656</ArticleId><ArticleId IdType="doi">10.1006/viro.2001.0943</ArticleId></ArticleIdList></Reference><Reference><Citation>Oda T, Ohka S, Nomoto A. Ligand stimulation of CD155alpha inhibits cell adhesion and enhances cell migration in fibroblasts. Biochem Biophys Res Commun. 2004;319(4):1253&#x2013;64.</Citation><ArticleIdList><ArticleId IdType="pubmed">15194502</ArticleId><ArticleId IdType="doi">10.1016/j.bbrc.2004.05.111</ArticleId></ArticleIdList></Reference><Reference><Citation>Chandramohan V, Bryant JD, Piao H, Keir ST, Lipp ES, Lefaivre M, et al. Validation of an immunohistochemistry assay for detection of CD155, the poliovirus receptor. Malignant Gliomas Arch Pathol Lab Med. 2017;141(12):1697&#x2013;704.</Citation><ArticleIdList><ArticleId IdType="pubmed">28829151</ArticleId><ArticleId IdType="doi">10.5858/arpa.2016-0580-OA</ArticleId></ArticleIdList></Reference><Reference><Citation>Brown MC, Gromeier M. Cytotoxic and immunogenic mechanisms of recombinant oncolytic poliovirus. Curr Opin Virol. 2015;13:81&#x2013;5.</Citation><ArticleIdList><ArticleId IdType="pubmed">26083317</ArticleId><ArticleId IdType="pmc">4550519</ArticleId><ArticleId IdType="doi">10.1016/j.coviro.2015.05.007</ArticleId></ArticleIdList></Reference><Reference><Citation>Desjardins A, Gromeier M, Herndon JE 2nd, Beaubier N, Bolognesi DP, Friedman AH, et al. Recurrent glioblastoma treated with recombinant poliovirus. N Engl J Med. 2018;379(2):150&#x2013;61.</Citation><ArticleIdList><ArticleId IdType="pubmed">29943666</ArticleId><ArticleId IdType="pmc">6065102</ArticleId><ArticleId IdType="doi">10.1056/NEJMoa1716435</ArticleId></ArticleIdList></Reference><Reference><Citation>Ochiai H, Campbell SA, Archer GE, Chewning TA, Dragunsky E, Ivanov A, et al. Targeted therapy for glioblastoma multiforme neoplastic meningitis with intrathecal delivery of an oncolytic recombinant poliovirus. Clin Cancer Res. 2006;12(4):1349&#x2013;54.</Citation><ArticleIdList><ArticleId IdType="pubmed">16489093</ArticleId><ArticleId IdType="doi">10.1158/1078-0432.CCR-05-1595</ArticleId></ArticleIdList></Reference><Reference><Citation>Morimoto K, Satoh-Yamaguchi K, Hamaguchi A, Inoue Y, Takeuchi M, Okada M, et al. Interaction of cancer cells with platelets mediated by Necl-5/poliovirus receptor enhances cancer cell metastasis to the lungs. Oncogene. 2008;27(3):264&#x2013;73.</Citation><ArticleIdList><ArticleId IdType="pubmed">17637752</ArticleId><ArticleId IdType="doi">10.1038/sj.onc.1210645</ArticleId></ArticleIdList></Reference><Reference><Citation>Liu L, Wang Y, Geng C, Wang A, Han S, You X, et al. CD155 promotes the progression of cervical cancer cells through AKT/mTOR and NF-kappaB pathways. Front Oncol. 2021;11: 655302.</Citation><ArticleIdList><ArticleId IdType="pubmed">34164340</ArticleId><ArticleId IdType="pmc">8216081</ArticleId><ArticleId IdType="doi">10.3389/fonc.2021.655302</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhao K, Ma L, Feng L, Huang Z, Meng X, Yu J. CD155 overexpression correlates with poor prognosis in primary small cell carcinoma of the esophagus. Front Mol Biosci. 2020;7: 608404.</Citation><ArticleIdList><ArticleId IdType="pubmed">33490104</ArticleId><ArticleId IdType="doi">10.3389/fmolb.2020.608404</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang J, Zhu Y, Wang Q, Kong Y, Sheng H, Guo J, et al. Poliovirus receptor CD155 is up-regulated in muscle-invasive bladder cancer and predicts poor prognosis. Urol Oncol. 2020;38(2):41.e11-41.e18.</Citation><ArticleIdList><ArticleId IdType="pubmed">31383549</ArticleId><ArticleId IdType="doi">10.1016/j.urolonc.2019.07.006</ArticleId></ArticleIdList></Reference><Reference><Citation>Masson D, Jarry A, Baury B, Blanchardie P, Laboisse C, Lustenberger P, et al. Overexpression of the CD155 gene in human colorectal carcinoma. Gut. 2001;49(2):236&#x2013;40.</Citation><ArticleIdList><ArticleId IdType="pubmed">11454801</ArticleId><ArticleId IdType="pmc">1728395</ArticleId><ArticleId IdType="doi">10.1136/gut.49.2.236</ArticleId></ArticleIdList></Reference><Reference><Citation>Molfetta R, Zitti B, Lecce M, Milito ND, Stabile H, Fionda C, et al. CD155: a multi-functional molecule in tumor progression. Int J Mol Sci. 2020;21(3):922.</Citation><ArticleIdList><ArticleId IdType="pubmed">32019260</ArticleId><ArticleId IdType="pmc">7037299</ArticleId><ArticleId IdType="doi">10.3390/ijms21030922</ArticleId></ArticleIdList></Reference><Reference><Citation>Sloan KE, Eustace BK, Stewart JK, Zehetmeier C, Torella C, Simeone M, et al. CD155/PVR plays a key role in cell motility during tumor cell invasion and migration. BMC Cancer. 2004;7(4):73.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/1471-2407-4-73</ArticleId></ArticleIdList></Reference><Reference><Citation>Enloe BM, Jay DG. Inhibition of Necl-5 (CD155/PVR) reduces glioblastoma dispersal and decreases MMP-2 expression and activity. J Neurooncol. 2011;102(2):225&#x2013;35.</Citation><ArticleIdList><ArticleId IdType="pubmed">20680398</ArticleId><ArticleId IdType="doi">10.1007/s11060-010-0323-5</ArticleId></ArticleIdList></Reference><Reference><Citation>Chauvin JM, Zarour HM. TIGIT in cancer immunotherapy. J Immunother Cancer. 2020;8(2):e000957.</Citation><ArticleIdList><ArticleId IdType="pubmed">32900861</ArticleId><ArticleId IdType="pmc">7477968</ArticleId><ArticleId IdType="doi">10.1136/jitc-2020-000957</ArticleId></ArticleIdList></Reference><Reference><Citation>Johnston Robert J, Comps-Agrar L, Hackney J, Yu X, Huseni M, Yang Y, et al. The immunoreceptor TIGIT regulates antitumor and antiviral CD8&lt;sup&gt;+&lt;/sup&gt; T cell effector function. Cancer Cell. 2014;26(6):923&#x2013;37.</Citation><ArticleIdList><ArticleId IdType="pubmed">25465800</ArticleId><ArticleId IdType="doi">10.1016/j.ccell.2014.10.018</ArticleId></ArticleIdList></Reference><Reference><Citation>Dixon KO, Schorer M, Nevin J, Etminan Y, Amoozgar Z, Kondo T, et al. Functional anti-TIGIT antibodies regulate development of autoimmunity and antitumor immunity. J Immunol. 2018;200(8):3000&#x2013;7.</Citation><ArticleIdList><ArticleId IdType="pubmed">29500245</ArticleId><ArticleId IdType="doi">10.4049/jimmunol.1700407</ArticleId></ArticleIdList></Reference><Reference><Citation>Hung AL, Maxwell R, Theodros D, Belcaid Z, Mathios D, Luksik AS, et al. TIGIT and PD-1 dual checkpoint blockade enhances antitumor immunity and survival in GBM. OncoImmunology. 2018;7(8):e1466769.</Citation><ArticleIdList><ArticleId IdType="pubmed">30221069</ArticleId><ArticleId IdType="pmc">6136875</ArticleId><ArticleId IdType="doi">10.1080/2162402X.2018.1466769</ArticleId></ArticleIdList></Reference><Reference><Citation>Technology CS (2020) Certificate of Analysis, Product Number 13544, Product Name PVR/CD155.</Citation></Reference><Reference><Citation>Gromeier M, Solecki D, Patel DD, Wimmer E. Expression of the human poliovirus receptor/CD155 gene during development of the central nervous system: implications for the pathogenesis of poliomyelitis. Virology. 2000;273(2):248&#x2013;57.</Citation><ArticleIdList><ArticleId IdType="pubmed">10915595</ArticleId><ArticleId IdType="doi">10.1006/viro.2000.0418</ArticleId></ArticleIdList></Reference><Reference><Citation>Takenaka MC, Gabriely G, Rothhammer V, Mascanfroni ID, Wheeler MA, Chao CC, et al. Control of tumor-associated macrophages and T cells in glioblastoma via AHR and CD39. Nat Neurosci. 2019;22(5):729&#x2013;40.</Citation><ArticleIdList><ArticleId IdType="pubmed">30962630</ArticleId><ArticleId IdType="pmc">8052632</ArticleId><ArticleId IdType="doi">10.1038/s41593-019-0370-y</ArticleId></ArticleIdList></Reference><Reference><Citation>Gabriely G, Quintana FJ. Role of AHR in the control of GBM-associated myeloid cells. Semin Cancer Biol. 2020;64:13&#x2013;8.</Citation><ArticleIdList><ArticleId IdType="pubmed">31128300</ArticleId><ArticleId IdType="doi">10.1016/j.semcancer.2019.05.014</ArticleId></ArticleIdList></Reference><Reference><Citation>McKay ZP, Brown MC, Gromeier M. Aryl hydrocarbon receptor signaling controls CD155 expression on macrophages and mediates tumor immunosuppression. J Immunol. 2021;206(6):1385&#x2013;94.</Citation><ArticleIdList><ArticleId IdType="pubmed">33504618</ArticleId><ArticleId IdType="doi">10.4049/jimmunol.2000792</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>